Bulletin Board, Published December 2013
Treatment, Published December 2013
A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.
Basic Science, Published November 2013
A meta-analysis of 13 genome-wide association studies of African Americans’ smoking patterns confirms the significance of genetic variation in region 15q25.1. The analysis also tentatively implicates several genome locations that have not previously been associated with smoking behaviors.
Treatment, Published November 2013
More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.
Prevention, Published November 2013
Women who reached their majority in states with policies that restricted teens’ access to tobacco products were less likely to smoke from ages 18-34 than women in states without those policies. The research did not demonstrate that the policies had a comparable impact on men’s smoking.
NIDA Seeks Applications for Women and Sex/Gender Differences Junior Investigator Travel Awards for CPDD
Bulletin Board, Published November 2013
NIDA plans to provide $750 travel awards to 27 junior investigators to present their research on women or sex/gender differences in any area of drug abuse at the annual meeting of the College on Problems of Drug Dependence (CPDD) in San Juan, Puerto Rico, June 14‒19, 2014. Deadline to apply is December 2, 2013.
Public Health, Published October 2013
People with cannabis use disorder (CUD) are likely also to have social anxiety disorder (SAD), and comorbid SAD is associated with greater severity of cannabis-related problems. These findings highlight the importance of assessing CUD patients for SAD, as that disorder can be both a contributing cause and a consequence of CUD. Treating both disorders may be a key to helping patients recover from each.
NIDA @ Work, Published September 2013
Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.
Basic Science, Published August 2013
Prevention, Published August 2013
Regular cannabis use that starts in adolescence strips away IQ, a NIDA-supported study suggests. Participants who initiated weekly cannabis use before age 18 dropped IQ points in proportion to how long they persisted in using the drug. Persistent cannabis users’ cognitive difficulties were evident to friends and family and measurable on a battery of tests.
Animation: Testing a Prospective Medication To Help People Avoid Relapse. Watch Now
Animation: The Rise and Fall of the Cocaine High. Watch Now